Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Change in Inventory (2016 - 2025)

Historic Change in Inventory for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to -$5.9 million.

  • Amphastar Pharmaceuticals' Change in Inventory fell 18017.51% to -$5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.5 million, marking a year-over-year increase of 17946.3%. This contributed to the annual value of $48.8 million for FY2024, which is 273045.24% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Change in Inventory stood at -$5.9 million for Q3 2025, which was down 18017.51% from $4.8 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' Change in Inventory's 5-year high stood at $31.1 million during Q1 2025, with a 5-year trough of -$7.0 million in Q4 2021.
  • Its 5-year average for Change in Inventory is $4.8 million, with a median of $4.1 million in 2021.
  • Its Change in Inventory has fluctuated over the past 5 years, first crashed by 30926.87% in 2023, then surged by 382947.76% in 2024.
  • Amphastar Pharmaceuticals' Change in Inventory (Quarter) stood at -$7.0 million in 2021, then skyrocketed by 83.26% to -$1.2 million in 2022, then plummeted by 309.27% to -$4.8 million in 2023, then skyrocketed by 608.37% to $24.5 million in 2024, then tumbled by 123.95% to -$5.9 million in 2025.
  • Its last three reported values are -$5.9 million in Q3 2025, $4.8 million for Q2 2025, and $31.1 million during Q1 2025.